Free Trial

Best Penny Stocks Under 50 Cents Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.50 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.50.

Show:
Pineapple Energy stock logo

#1 - Pineapple Energy

NASDAQ:PEGY
Stock Price:
$0.19 (-$0.05)
Market Cap:
$20.62 million
Average Trading Volume:
44.61 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.50 (1,215.8% Upside)
Pineapple Energy Inc. engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. The company develops and manufactures energy management software and hardware, such as energy management control devices on solar systems that are paired with batteries. It primarily serves residential homeowners, as well as commercial owners, other municipal customers, energy services companies, and other utilities. Pineapple Energy Inc. was founded in 1969 and is based in Minnetonka, Minnesota.
Kintara Therapeutics stock logo

#2 - Kintara Therapeutics

NASDAQ:KTRA
Stock Price:
$0.31 (-$0.01)
P/E Ratio:
-0.08
Market Cap:
$17.17 million
Average Trading Volume:
14.30 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Barnes & Noble Education stock logo

#3 - Barnes & Noble Education

NYSE:BNED
Stock Price:
$0.45 (-$0.32)
P/E Ratio:
-0.29
Market Cap:
$23.92 million
Average Trading Volume:
9.07 million shares
Consensus Rating:
Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.63 (483.3% Upside)
Barnes & Noble Education, Inc. operates bookstores for college and university campuses, and K-12 institutions in the United States. It operates through Retail and Wholesale segments. The company sells and rents new and used print textbooks, digital textbooks, and publisher hosted digital courseware through physical and virtual bookstores, as well as directly to students through Textbooks.com. In addition, it offers First Day and First Day Complete access programs; and general merchandise, including collegiate and athletic apparel, school spirit products, lifestyle products, technology products, supplies, graduation products, and convenience items. Further, the company sources, sells, and distributes new and used textbooks; and sells hardware and a software suite of applications that provides inventory management and point-of-sale solutions to approximately 340 college bookstores. Additionally, it offers direct-to-student services. The company operates physical college and university bookstores; virtual bookstores; True Spirit e-commerce websites; pop-up retail locations; customized cafés and stand-alone convenience stores; and a media channel for brands targeting the college demographic. Barnes & Noble Education, Inc. was founded in 1965 and is headquartered in Basking Ridge, New Jersey.
KULR Technology Group stock logo

#4 - KULR Technology Group

NYSEAMERICAN:KULR
Stock Price:
0.33 (+0.01)
P/E Ratio:
-1.81
Market Cap:
$59.63 million
Average Trading Volume:
8.28 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
KULR Technology Group, Inc., through its subsidiary, KULR Technology Corporation, develops and commercializes thermal management technologies for electronics, batteries, and other components applications in the United States. It provides lithium-ion battery thermal runaway shields; automated battery cell screening and test systems; cellchecks; safecases; fiber thermal interface materials; phase change material heat sinks; internal short circuit devices; and CRUX cathodes. The company's technologies are used in electric vehicles, energy storage, battery recycling transportation, cloud computing, and 5G communication devices. It sells its products for applications, such as lithium-ion battery energy storage, electric vehicles, 5G communication, cloud computer infrastructure, consumer, and industrial devices. The company was formerly known as KT High-Tech Marketing Inc. and changed its name to KULR Technology Group, Inc. in August 2018. KULR Technology Group, Inc. was founded in 2013 and is based in San Diego, California.
Workhorse Group stock logo

#5 - Workhorse Group

NASDAQ:WKHS
Stock Price:
$0.19 (-$0.00)
P/E Ratio:
-0.36
Market Cap:
$73.13 million
Average Trading Volume:
12.52 million shares
Consensus Rating:
Hold (1 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$1.50 (669.6% Upside)
Workhorse Group Inc., a technology company, engages in design, manufacture, and sale of zero-emission commercial vehicles in the United States. The company offers commercial vehicles under the Workhorse brand. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015. Workhorse Group Inc. was founded in 2007 and is headquartered in Sharonville, Ohio.
Cybin stock logo

#6 - Cybin

NYSEAMERICAN:CYBN
Stock Price:
$0.35 (+$0.00)
P/E Ratio:
-1.67
Market Cap:
$143.80 million
Average Trading Volume:
4.48 million shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.25 (1,114.3% Upside)
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

#7 - Cybin

NYSE:CYBN
Stock Price:
$0.35 (+$0.00)
P/E Ratio:
-1.67
Market Cap:
$143.80 million
Average Trading Volume:
4.48 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.00 (1,328.6% Upside)
Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.
Cybin stock logo

#8 - Cybin

OTCMKTS:CYBN
Stock Price:
$0.35 (+$0.00)
P/E Ratio:
-1.84
Market Cap:
$143.80 million
Average Trading Volume:
4.48 million shares
Consensus Rating:
Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$7.50 (2,042.9% Upside)
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
Akoustis Technologies stock logo

#9 - Akoustis Technologies

NASDAQ:AKTS
Stock Price:
$0.22 (+$0.02)
P/E Ratio:
-0.22
Market Cap:
$21.21 million
Average Trading Volume:
7.16 million shares
Consensus Rating:
Hold (1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1.92 (791.5% Upside)
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States, Asia, Europe, and internationally. It operates through Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment provides engineering review and backend packaging services. Its RF Filters segment sells amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was founded in 2013 and is headquartered in Huntersville, North Carolina.
Banzai International stock logo

#10 - Banzai International

NASDAQ:BNZI
Stock Price:
$0.21 (+$0.01)
Market Cap:
$4.46 million
Average Trading Volume:
6.92 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.00 (1,354.2% Upside)
Banzai International, Inc., a marketing technology company, provides data-driven marketing and sales solutions for various businesses in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Its products include Demio, a browser-based webinar platform with data and marketing features designed to help businesses engage with their audience through live events and on-demand, interactive video content; Boost, a SaaS solution for social sharing by event registrants; and Reach, a Saas and managed service to increase registration and attendance of marketing events. The company serves healthcare, financial services, e-commerce, technology, media, and other industries. Banzai International, Inc. was founded in 2015 and is based in Bainbridge Island, Washington.
Ontrak stock logo

#11 - Ontrak

NASDAQ:OTRK
Stock Price:
$0.25 (-$0.01)
P/E Ratio:
-0.06
Market Cap:
$12.04 million
Average Trading Volume:
4.43 million shares
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.00 (1,493.6% Upside)
Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. Ontrak, Inc. was incorporated in 2003 and is headquartered in Miami, Florida.
Microvast stock logo

#12 - Microvast

NASDAQ:MVST
Stock Price:
$0.37 (+$0.03)
P/E Ratio:
-1.17
Market Cap:
$118.60 million
Average Trading Volume:
2.96 million shares
Consensus Rating:
Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.50 (1,103.5% Upside)
Microvast Holdings, Inc. provides battery technologies for electric vehicles and energy storage solutions. The company offers a range of cell chemistries, such as lithium titanate oxide, lithium iron phosphate, and nickel manganese cobalt version 1 and 2. It also designs, develops, and manufactures battery components, such as cathode, anode, electrolyte, and separator. In addition, the company offers battery solutions for commercial vehicles and energy storage systems. Its commercial vehicle markets cover buses, trains, mining trucks, marine and port vehicles, and automated guided and specialty vehicles, as well as light, medium, heavy-duty trucks. It operates China, rest of the Asia Pacific, Europe, and the United States. Microvast Holdings, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Akili stock logo

#13 - Akili

NASDAQ:AKLI
Stock Price:
$0.42 (+$0.00)
P/E Ratio:
-0.69
Market Cap:
$33.11 million
Average Trading Volume:
2.50 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.00 (851.0% Upside)
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.
Nuwellis stock logo

#14 - Nuwellis

NASDAQ:NUWE
Stock Price:
$0.26 (-$0.01)
P/E Ratio:
-0.03
Market Cap:
$4.73 million
Average Trading Volume:
3.98 million shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Senseonics stock logo

#15 - Senseonics

NYSE:SENS
Stock Price:
$0.43 (-$0.00)
P/E Ratio:
-3.07
Market Cap:
$228.28 million
Average Trading Volume:
2.31 million shares
Consensus Rating:
Hold (1 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$1.25 (190.7% Upside)
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Chicken Soup for the Soul Entertainment stock logo

#16 - Chicken Soup for the Soul Entertainment

NASDAQ:CSSE
Stock Price:
$0.30 (+$0.01)
P/E Ratio:
-0.02
Market Cap:
$9.62 million
Average Trading Volume:
3.05 million shares
Consensus Rating:
Hold (2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.00 (1,246.3% Upside)
Chicken Soup for the Soul Entertainment, Inc. operates as an advertising-supported video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Redbox, Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Popcornflix Comedy, FrightPix, Truli, and Españolflix, as well as Pivotshare, subscription VOD platform. The company also operates Redbox Free Live TV, a free ad-supported streaming television (FAST) service with various channels as well as a transactional video-on-demand (TVOD) service; and a network of kiosks for DVD rentals. In addition, it is involved in the creation, acquisition, and distribution of films and TV series; and licensing of content through theatrical, home video, pay-per-view, free, cable and pay television, and subscription and advertising video-on-demand platforms. The company was founded in 1993 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul Productions, LLC.
American Well stock logo

#17 - American Well

NYSE:AMWL
Stock Price:
$0.43 (+$0.03)
P/E Ratio:
-0.35
Market Cap:
$126.56 million
Average Trading Volume:
1.99 million shares
Consensus Rating:
Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$0.80 (87.4% Upside)
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members. It provides Carepoint devices comprising carts, peripherals, tablets, and TVs, which serve as digital access points in clinical settings. In addition, the company offers Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, acute psychiatry, lactation counseling, and nutrition services. Further, it provides professional services to facilitate implementation, workflow design, systems integration, and service expansion for its products, as well as patient and provider engagement services. The company sells its products through field sales professionals, channel partners, and value-added resellers. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Cue Health stock logo

#18 - Cue Health

NASDAQ:HLTH
Stock Price:
$0.07 (-$0.00)
P/E Ratio:
-0.03
Market Cap:
$10.75 million
Average Trading Volume:
12.21 million shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Cue Health Inc. operates as a healthcare technology company. It provides the Cue Health platform that offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a range of health and wellness needs. It offers Cue Integrated Care platform comprising hardware, software, and diagnostic components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, including integration with electronic medical record system, pharmacies and last-mile delivery, clinician networks, and laboratories. The company also provides COVID-19 testing kits. The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.
BioVie stock logo

#19 - BioVie

NASDAQ:BIVI
Stock Price:
$0.46 (+$0.02)
P/E Ratio:
-0.48
Market Cap:
$27.80 million
Average Trading Volume:
1.72 million shares
Consensus Rating:
Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.00 (1,656.3% Upside)
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
BIOLASE stock logo

#20 - BIOLASE

NASDAQ:BIOL
Stock Price:
$0.17 (-$0.02)
P/E Ratio:
-0.01
Market Cap:
$5.71 million
Average Trading Volume:
4.02 million shares
Consensus Rating:
Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$0.40 (134.2% Upside)
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Charge Enterprises stock logo

#21 - Charge Enterprises

NASDAQ:CRGE
Stock Price:
$0.02 (-$0.01)
P/E Ratio:
-0.10
Market Cap:
$4.52 million
Average Trading Volume:
32.32 million shares
Consensus Rating:
Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.50 (21,328.6% Upside)
Charge Enterprises Inc. operates as an electrical, broadband, and electric vehicle (EV) charging infrastructure company. The company provides clients with end-to-end project management services, including advising, designing, engineering, acquiring and installing equipment, monitoring, servicing, and maintenance. It operates in two segments, Infrastructure and Telecommunications. The Infrastructure segment offers broadband and wireless, electrical contracting, electric vehicle charging, and fleet services. The Telecommunications segment provides internet-protocol-based and time-division multiplexing access for transport of long-distance voice and data minutes; domestic switching and related peripheral equipment services, and carrier-grade routers and switches for internet and circuit-based services, as well as connection of voice calls and data services. The company was formerly known as TransWorld Holdings Inc and changed its name to Charge Enterprises, Inc. in January 2021. Charge Enterprises, Inc. was incorporated in 2003 and is based in New York, New York. On March 7, 2024, Charge Enterprises, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Lyra Therapeutics stock logo

#22 - Lyra Therapeutics

NASDAQ:LYRA
Stock Price:
$0.33 (-$0.00)
P/E Ratio:
-0.27
Market Cap:
$20.00 million
Average Trading Volume:
2.03 million shares
Consensus Rating:
Hold (1 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$7.13 (2,072.3% Upside)
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
BiomX stock logo

#23 - BiomX

NYSEAMERICAN:PHGE
Stock Price:
$0.40 (-$0.02)
P/E Ratio:
-0.66
Market Cap:
$27.92 million
Average Trading Volume:
1.66 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.00 (400.0% Upside)
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Arqit Quantum stock logo

#24 - Arqit Quantum

NASDAQ:ARQQ
Stock Price:
$0.39 (-$0.01)
Market Cap:
$64.97 million
Average Trading Volume:
1.45 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.00 (412.8% Upside)
Arqit Quantum Inc. provides cybersecurity services through satellite and terrestrial platforms in the United Kingdom. It offers QuantumCloud, a Platform as a Service that creates unbreakable software encryption keys. The company also provides maintenance and support, and professional services. Arqit Quantum Inc. is based in London, the United Kingdom.
Renalytix stock logo

#25 - Renalytix

NASDAQ:RNLX
Stock Price:
$0.41 (+$0.05)
P/E Ratio:
-1.06
Market Cap:
$32.01 million
Average Trading Volume:
1.26 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.00 (1,105.4% Upside)
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

More Stock Ideas from MarketBeat